127 related articles for article (PubMed ID: 36445254)
1. LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL.
Ko A; Hasanain M; Oh YT; D'Angelo F; Sommer D; Frangaj B; Tran S; Bielle F; Pollo B; Paterra R; Mokhtari K; Soni RK; Peyre M; Eoli M; Papi L; Kalamarides M; Sanson M; Iavarone A; Lasorella A
Cancer Discov; 2023 Mar; 13(3):702-723. PubMed ID: 36445254
[TBL] [Abstract][Full Text] [Related]
2. Germline Mutations for Novel Candidate Predisposition Genes in Sporadic Schwannomatosis.
Min BJ; Kang YK; Chung YG; Seo ME; Chang KB; Joo MW
Clin Orthop Relat Res; 2020 Nov; 478(11):2442-2450. PubMed ID: 32281771
[TBL] [Abstract][Full Text] [Related]
3. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis.
Smith MJ; Isidor B; Beetz C; Williams SG; Bhaskar SS; Richer W; O'Sullivan J; Anderson B; Daly SB; Urquhart JE; Fryer A; Rustad CF; Mills SJ; Samii A; du Plessis D; Halliday D; Barbarot S; Bourdeaut F; Newman WG; Evans DG
Neurology; 2015 Jan; 84(2):141-7. PubMed ID: 25480913
[TBL] [Abstract][Full Text] [Related]
4. Coexistence of schwannomatosis and glioblastoma in two families.
Deiller C; Van-Gils J; Zordan C; Tinat J; Loiseau H; Fabre T; Delleci C; Cohen J; Vidaud M; Parfait B; Goizet C
Eur J Med Genet; 2019 Aug; 62(8):103680. PubMed ID: 31128261
[TBL] [Abstract][Full Text] [Related]
5. Pain correlates with germline mutation in schwannomatosis.
Jordan JT; Smith MJ; Walker JA; Erdin S; Talkowski ME; Merker VL; Ramesh V; Cai W; Harris GJ; Bredella MA; Seijo M; Suuberg A; Gusella JF; Plotkin SR
Medicine (Baltimore); 2018 Feb; 97(5):e9717. PubMed ID: 29384852
[TBL] [Abstract][Full Text] [Related]
6. Expanding the mutational spectrum of LZTR1 in schwannomatosis.
Paganini I; Chang VY; Capone GL; Vitte J; Benelli M; Barbetti L; Sestini R; Trevisson E; Hulsebos TJ; Giovannini M; Nelson SF; Papi L
Eur J Hum Genet; 2015 Jul; 23(7):963-8. PubMed ID: 25335493
[TBL] [Abstract][Full Text] [Related]
7. The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.
Kehrer-Sawatzki H; Farschtschi S; Mautner VF; Cooper DN
Hum Genet; 2017 Feb; 136(2):129-148. PubMed ID: 27921248
[TBL] [Abstract][Full Text] [Related]
8. A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas.
Caltabiano R; Magro G; Polizzi A; Praticò AD; Ortensi A; D'Orazi V; Panunzi A; Milone P; Maiolino L; Nicita F; Capone GL; Sestini R; Paganini I; Muglia M; Cavallaro S; Lanzafame S; Papi L; Ruggieri M
Childs Nerv Syst; 2017 Jun; 33(6):933-940. PubMed ID: 28365909
[TBL] [Abstract][Full Text] [Related]
9. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas.
Piotrowski A; Xie J; Liu YF; Poplawski AB; Gomes AR; Madanecki P; Fu C; Crowley MR; Crossman DK; Armstrong L; Babovic-Vuksanovic D; Bergner A; Blakeley JO; Blumenthal AL; Daniels MS; Feit H; Gardner K; Hurst S; Kobelka C; Lee C; Nagy R; Rauen KA; Slopis JM; Suwannarat P; Westman JA; Zanko A; Korf BR; Messiaen LM
Nat Genet; 2014 Feb; 46(2):182-7. PubMed ID: 24362817
[TBL] [Abstract][Full Text] [Related]
10. LZTR1: A promising adaptor of the CUL3 family.
Zhang H; Cao X; Wang J; Li Q; Zhao Y; Jin X
Oncol Lett; 2021 Jul; 22(1):564. PubMed ID: 34113392
[TBL] [Abstract][Full Text] [Related]
11. Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling.
Motta M; Fidan M; Bellacchio E; Pantaleoni F; Schneider-Heieck K; Coppola S; Borck G; Salviati L; Zenker M; Cirstea IC; Tartaglia M
Hum Mol Genet; 2019 Mar; 28(6):1007-1022. PubMed ID: 30481304
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the frequency of loss-of-function LZTR1 variants between schwannomatosis patients and the general population.
Deng F; Evans DG; Smith MJ
Hum Mutat; 2022 Jul; 43(7):919-927. PubMed ID: 35391499
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.
Kehrer-Sawatzki H; Kluwe L; Friedrich RE; Summerer A; Schäfer E; Wahlländer U; Matthies C; Gugel I; Farschtschi S; Hagel C; Cooper DN; Mautner VF
Hum Genet; 2018 Jul; 137(6-7):543-552. PubMed ID: 30006736
[TBL] [Abstract][Full Text] [Related]
14. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.
Ghiso E; Migliore C; Ciciriello V; Morando E; Petrelli A; Corso S; De Luca E; Gatti G; Volante M; Giordano S
Neoplasia; 2017 Dec; 19(12):1012-1021. PubMed ID: 29136529
[TBL] [Abstract][Full Text] [Related]
15. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
[TBL] [Abstract][Full Text] [Related]
16. Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas.
Wu Z; Bai F; Fan L; Pang W; Han R; Wang J; Liu Y; Yan X; Duan H; Xing L
Hum Pathol; 2015 Dec; 46(12):1935-44. PubMed ID: 26475093
[TBL] [Abstract][Full Text] [Related]
17. Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination.
Steklov M; Pandolfi S; Baietti MF; Batiuk A; Carai P; Najm P; Zhang M; Jang H; Renzi F; Cai Y; Abbasi Asbagh L; Pastor T; De Troyer M; Simicek M; Radaelli E; Brems H; Legius E; Tavernier J; Gevaert K; Impens F; Messiaen L; Nussinov R; Heymans S; Eyckerman S; Sablina AA
Science; 2018 Dec; 362(6419):1177-1182. PubMed ID: 30442762
[TBL] [Abstract][Full Text] [Related]
18. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
[TBL] [Abstract][Full Text] [Related]
19. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG
Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782
[TBL] [Abstract][Full Text] [Related]
20. Unilateral vestibular schwannoma in a patient with schwannomatosis in the absence of LZTR1 mutation.
Mehta GU; Feldman MJ; Wang H; Ding D; Chittiboina P
J Neurosurg; 2016 Dec; 125(6):1469-1471. PubMed ID: 26848914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
